Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France.
Centre de Recherche en Cancérologie de Marseille (CRCM, Marseille Cancer Research Centre), Inserm UMR1068, CNRS UMR7258 and Aix-Marseille University UM105, Marseille, France.
Eur Respir Rev. 2018 Mar 14;27(147). doi: 10.1183/16000617.0098-2017. Print 2018 Mar 31.
Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries. Consequently, drug repurposing appears as an attractive strategy for drug development in MPM, since the known pharmacology and safety profile based on previous approvals of repurposed drugs allows for faster time-to-market for patients and lower treatment cost. This is critical in low- and middle-income countries where access to expensive drugs is limited. This review assesses the published preclinical and clinical data about drug repurposing in MPM.In this review, we identified 11 therapeutic classes that could be repositioned in mesothelioma. Most of these treatments have been evaluated , half have been evaluated in animal models of MPM and only three ( valproate, thalidomide and zoledronic acid) have been investigated in clinical trials, with limited benefits so far. Efforts could be coordinated to pursue further investigations and test promising drugs identified in preclinical experiments in appropriately designed clinical trials.
药物再利用是指将已知药物用于新的适应症。恶性胸膜间皮瘤（MPM）是一种罕见的癌症，预后不良。到目前为止，这种疾病只批准了几种治疗方法。然而，预计其发病率将显著增加，特别是在发展中国家。因此，药物再利用似乎是 MPM 药物开发的一种有吸引力的策略，因为基于先前批准的再利用药物的已知药理学和安全性概况，可以为患者更快地推向市场，并降低治疗成本。这在昂贵药物获取有限的低收入和中等收入国家尤为关键。本综述评估了已发表的关于 MPM 药物再利用的临床前和临床数据。在本综述中，我们确定了 11 种可用于间皮瘤的治疗类别。这些治疗方法中的大多数都已经过评估，其中一半已经在 MPM 的动物模型中进行了评估，只有三种（丙戊酸、沙利度胺和唑来膦酸）在临床试验中进行了研究，迄今为止获益有限。可以协调努力，在适当设计的临床试验中进一步研究和测试临床前实验中确定的有前途的药物。
